Retatrutide: what it is, in plain terms
Retatrutide often appears in the same headlines as Ozempic and Mounjaro. This page sets out what the compound is, calmly and without the hype.
On this page
The compound in brief
Retatrutide is a peptide. That means it is a short string of amino acids, produced synthetically. It is designed to mimic three hormones the gut and pancreas release in response to food. It sits in the same wider group as semaglutide and tirzepatide, the active ingredients of Ozempic, Wegovy, Mounjaro and Zepbound. The difference is reach. Retatrutide engages three receptor targets at the same time. That is where the label “triple agonist” comes from.
Developer and reasons for attention
Eli Lilly, which also developed tirzepatide, is behind retatrutide. Its internal code is LY3437943. Attention follows the clinical data. Its trials have recorded some of the biggest average reductions in body weight yet seen for this drug class. For that reason commentators often frame it as a possible successor to today's GLP-1 medicines.
What the research describes
Published studies describe a combined effect from engaging the GLP-1, GIP and glucagon receptors at once. Appetite falls. Blood glucose becomes more stable. Energy expenditure rises. The idea is that three signals together go further than the one or two used by earlier compounds. A fuller walk-through is in our mechanism explainer.
This mechanism summary is based on published literature and is given as research background only. It is not a claim of therapeutic effect.
Retatrutide and the GLP-1 class
Retatrutide does act at the GLP-1 receptor. Calling it simply “a GLP-1”, though, leaves out two thirds of the picture. Semaglutide targets GLP-1 alone. Tirzepatide pairs GLP-1 with GIP. Retatrutide adds glucagon to that pair. The precise description is a triple agonist inside the broader GLP-1 family. Our three-way GLP-1 comparison places each compound side by side.
Approval and legal position
No regulator has approved retatrutide as a medicine. In August 2026 it was still in Phase 3 testing. Material on the market is supplied for research use only and has not been tested or authorised for use in people. That category is called a research peptide. Our research-peptide primer explains the term. The regulatory path is covered in our article on FDA status.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315.
- ClinicalTrials.gov. Retatrutide (LY3437943): Phase 3 TRIUMPH studies. Trial records.
Frequently asked questions
What is retatrutide being studied for?
Obesity is the main focus. Trials have also enrolled people with type 2 diabetes and people with heart disease. It is not an approved treatment for any of these conditions.
Does retatrutide have another name?
Yes, its development code: LY3437943. There is no brand name yet, because it has not been approved.
Are retatrutide and Ozempic the same thing?
No. Ozempic is a brand of semaglutide, which acts on the GLP-1 receptor alone. Retatrutide is a separate investigational compound that acts on three receptors.
Which company develops retatrutide?
Eli Lilly and Company.